Alexander L Khokhlov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2409759/publications.pdf

Version: 2024-02-01

45 papers 10,022 citations

394421 19 h-index 35 g-index

47 all docs

47 docs citations

47 times ranked

11887 citing authors

#	Article	IF	CITATIONS
1	Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30 / 70. Journal of Clinical Pharmacology, 2022, , .	2.0	2
2	Efficacy and safety of GP40021 insulin lispro biphasic compared with Humalog Mix 25 in Type 2 diabetes mellitus patients. Journal of Comparative Effectiveness Research, 2021, 10, 55-66.	1.4	3
3	Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19. Farmakoekonomika, 2021, 14, 16-27.	1.2	1
4	Study of the availability of gene therapeutic drugs in the Russian Federation. Remedium Journal About the Russian Market of Medicines and Medical Equipment, 2021, , 69-75.	0.1	0
5	Industrial Pharmacy: The Way to Create a Product (Monograph Review). Pharmaceutical Chemistry Journal, 2020, 54, 544-546.	0.8	О
6	Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus <code>[®]</code>): a randomized open-label clinical trial. Journal of Comparative Effectiveness Research, 2020, 9, 263-273.	1.4	5
7	Risk management strategy for preventing the reduced treatment effectiveness from the position of drug interactions and polypharmacy in patients with coronary heart disease. Research Results in Pharmacology, 2020, 6, 85-92.	0.4	2
8	ĐŸĐ¾Đ¸ÑĐº Đ³ĐµĐ½ĐĐµÑ€Đ½Ñ‹Ñ Ñ€Đ°Đ∙Đ»Đ¸Ñ‡Đ¸Đ¹ Ñ"Đ°Ñ€Đ¼Đ°ĐºĐ¾ĐºĐ¸Đ½ĐµÑ,Đ¸Ñ‡ĐµÑĐºĐ,Ñ	Đ ;Đ:% €Đ°	'ĐฬеÑ,Ñ€Đ
9	Planning and evaluation of bioequivalence study of HMG-CoA reductase inhibito. Medical News of North Caucasus, 2020, 15 , .	0.1	O
10	Review of bioequivalence studies of cholecalciferol drugs. Research Results in Pharmacology, 2020, 6, 21-26.	0.4	o
11	Pharmacokinetic and Bioequivalence Study of Telzap AM® (Telmisartan/amlodipine Fixed-dose) Tj ETQq1 1 0.76 Subjects. Drug Development and Registration, 2020, 9, 155-163.	84314 rgB 0 . 6	T /Overlock 10 0
12	Modeling the Effect of Tocilizumab on The Case Fatality Rate In Patients With Severe Covid-19. International Journal of Pharmaceutical Research (discontinued), 2020, 12, .	0.1	0
13	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 526.	6.1	26
14	Stroke prevention in patients from Latin American countries with nonâ€valvular atrial fibrillation: Insights from the GARFIELDâ€AF registry. Clinical Cardiology, 2019, 42, 553-560.	1.8	16
15	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	2.7	45
16	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
17	Investigation Planning and Bioequivalence evaluation of Angiotensin II Receptor Antagonists. Pharmaceutical Chemistry Journal, 2019, 53, 680-684.	0.8	0
18	The results of experimental studies of the use of silver nanoparticles in tuberculosis drug-resistant pathogen. Medical News of North Caucasus, 2019, 14, .	0.1	1

#	Article	IF	CITATIONS
19	Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations. Acta Biomedica Scientifica, 2019, 4, 93-101.	0.2	1
20	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
21	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
22	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
23	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	2.5	80
24	Methodical approaches to bioassay of substances containing unstable functional groups. Research Results in Pharmacology, 2018, 4, 33-42.	0.3	0
25	Đ~ÑÑ,Đ¾Ñ€Đ¸Ñ•Đ°Đ°Ñ"еĐ′ры Ñ"Đ°Ñ€Đ¼Đ°Đ°Đ¾Đ»Đ¾Đ³Đ,Đ¸Đ¯Ñ€Đ¾ÑĐ»Đ°Đ²ÑĐ°Đ¾Đ3¾Đ3Đ¾ Đ³Đ¾ÑÑ	Ĭ∱ ᡚ ŶÑ€Ĭ	ÑÑ¢Đ²ĐμĐ½
26	INFLUENCE OF SEX DIFFERENCES ON PHARMACOKINETICS OF DRUGS WITHIN THE FRAMEWORK OF BIOEQUIVALENCE STUDIES OF GENERIC MEDICINAL PRODUCTS. Acta Biomedica Scientifica, 2018, 3, 94-105.	0.2	1
27	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	2.9	205
28	Impact of gender on event rates at 1â€year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	1.9	30
29	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	27.0	510
30	Quantitative Determination of Mycophenolic Acid in Human Blood Plasma by High-Performance Liquid Chromatography with Tandem Mass-Spectrometric Detection. Pharmaceutical Chemistry Journal, 2017, 51, 504-507.	0.8	0
31	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
32	Methidical approaches to bioassay of phenolic hydroxylenes contain substances. Medical News of North Caucasus, $2017, 12, \ldots$	0.1	2
33	The complex characteristics of the statins efficiency in ischemic stroke. Medical News of North Caucasus, 2017, 12, .	0.1	1
34	Effects of the lercanidipine–enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension. Journal of Hypertension, 2016, 34, 139-148.	0.5	10
35	Development of Clinical Pharmacology in the Russian Federation. Clinical Therapeutics, 2016, 38, 1218-1226.e1.	2.5	2
36	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334.	27.0	2,809

#	Article	IF	CITATIONS
37	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
38	Cause of Death and Predictors of Allâ€Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	3.7	127
39	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	2.2	222
40	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
41	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	2.2	74
42	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2013, 369, 2093-2104.	27.0	4,215
43	Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Advances in Therapy, 2010, 27, 731-742.	2.9	48
44	Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the kneeâ€" a subset analysis. Advances in Therapy, 2010, 27, 953-962.	2.9	31
45	Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutrition Research, 2009, 29, 298-304.	2.9	48